Last reviewed · How we verify
Renin-angiotensin system blockers
Renin-angiotensin system blockers inhibit the formation or action of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and decreasing cardiac workload.
Renin-angiotensin system blockers inhibit the formation or action of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and decreasing cardiac workload. Used for Hypertension, Heart failure, Post-myocardial infarction.
At a glance
| Generic name | Renin-angiotensin system blockers |
|---|---|
| Also known as | ramipril, irbesartan |
| Sponsor | Hospital Authority, Hong Kong |
| Drug class | ACE inhibitors / Angiotensin II receptor blockers (ARBs) |
| Target | ACE enzyme or AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
These drugs work by either blocking the enzyme ACE (angiotensin-converting enzyme) that produces angiotensin II, or by directly antagonizing the angiotensin II type 1 receptor (AT1). By reducing angiotensin II signaling, they cause vasodilation, decrease aldosterone secretion, and reduce sodium and water retention, leading to lower blood pressure and improved cardiac function.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
- Diabetic nephropathy
- Chronic kidney disease
Common side effects
- Cough (ACE inhibitors)
- Hyperkalemia
- Dizziness
- Fatigue
- Angioedema
- Hypotension
Key clinical trials
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Levosimendan in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Secondary Prevention of Cardiovascular Disease in the Elderly Trial (PHASE3)
- Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy (NA)
- Long-term Use of CCB and Breast Cancer Risk
- Preserving Kidney Function in Children With Chronic Kidney Disease
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Renin-angiotensin system blockers CI brief — competitive landscape report
- Renin-angiotensin system blockers updates RSS · CI watch RSS
- Hospital Authority, Hong Kong portfolio CI